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BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-
liposomal formulation (eribulin-LF) in patients with advanced solid tumours.
METHODS: Eligible patients with ECOG PS 0–1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days
1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5 mg/m2, with dose escalation in a 3+ 3 design. The dose-
expansion phase evaluated eribulin-LF in select tumour types. Primary objectives: maximum tolerated dose (MTD) and the
recommended dose/schedule of eribulin-LF.
RESULTS: Totally, 58 patients were enroled (median age= 62 years). The MTD was 1.4 mg/m2 (Schedule 1) or 1.5 mg/m2 (Schedule
2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and
increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile
neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30 h), but with a 5-fold greater
maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with
approximately 10% of patients in both schedules achieving partial responses.
CONCLUSIONS: Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in
solid tumours was observed.
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BACKGROUND
Eribulin-liposomal formulation (eribulin-LF) is a new formulation
designed to improve the therapeutic index of the drug by
encapsulating eribulin mesylate in the interior of the water phase
of liposomes. Eribulin mesylate is a nontaxane antineoplastic
agent that inhibits microtubule dynamics and prevents tumour
cell proliferation.1–3 Eribulin is a synthetic analogue of the natural
product, halichondrin B, isolated from the marine sponge
Halichondria okadai.3 Eribulin has a novel mode of action that
distinguishes it from other tubulin-targeted drugs, including vinca
alkaloids: it leads to irreversible mitotic blockade by binding to a
small number of high-affinity sites on growing (plus) ends of
microtubules to inhibit their growth, without having a measurable
effect on microtubule shortening.1,2,4 Nonmitotic effects of
eribulin include suppressing cancer cell migration and invasion,
reversing the epithelial-to-mesenchymal transition that has been
associated with a malignant phenotype and tumour vascular
remodelling resulting in increased perfusion.4,5
Eribulin is approved as a monotherapy for patients with
metastatic breast cancer (MBC) who have previously been treated
with at least 2 (in the United States) or 1 (in Europe) prior
chemotherapeutic regimens, including an anthracycline and a
taxane, in either adjuvant or metastatic settings.6–8 Furthermore, in
a phase 3 clinical trial of patients with advanced liposarcoma or
leiomyosarcoma, eribulin significantly prolonged overall survival
compared with dacarbazine, and consequently, eribulin is also
approved for unresectable or metastatic liposarcoma in patients
who have already received an anthracycline-containing regimen.7–9
A pooled analysis of 2 randomised phase 3 studies showed that
eribulin could significantly improve overall survival in patients with
human epidermal growth factor receptor 2 (HER2)-negative breast
cancer and in patients with triple-negative disease.10
The potential efficacy of eribulin can be compromised by dose
reductions and omissions due to toxicities, the most common
being neutropenia and peripheral neuropathy.7 However, the use
of PEGylated liposomes to encapsulate drugs can help reduce
systemic toxicity11 and optimise exposure to drug. The liposome
platform facilitates the selective delivery of pharmacologic agents
to tumour cells, increasing selective uptake by these cells and,
therefore, control of drug delivery.12 PEGylated liposomal drugs
offer several additional advantages, including enhanced perme-
ability and longer retention in tumour tissues and improved
efficacy.11,13
Preclinical experiments of eribulin-LF in mice suggested
improved pharmacokinetics characterised by slower clearance, a
lower volume of distribution, and a 1.5-fold higher exposure to
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free eribulin compared with eribulin mesylate.14,15 Eribulin-LF has
also demonstrated improved antitumour activity in a human
pharynx squamous cell carcinoma xenograft model compared
with eribulin mesylate.14
OBJECTIVES
This phase 1 first-in-human trial aimed to identify the maximum
tolerated dose (MTD), recommended phase 2 dose and schedule,
and to assess the safety, tolerability, pharmacokinetic and
preliminary efficacy of eribulin-LF in patients with advanced or
metastatic solid tumours, including breast, ovarian or endometrial
cancers.
METHODS
Study design
This phase 1, open-label, multicenter study comprised a dose-
escalation phase and a dose-expansion phase. The dose-escalation
phase consisted of a 3+ 3 design with 2 schedules: In Schedule 1,
eribulin-LF was administered as a 60-min intravenous (IV) infusion
on day 1 of a 21-day cycle and in Schedule 2, eribulin-LF was
administered as a 60-min IV infusion on day 1 and day 15 of a
28-day cycle. These schedules were chosen in anticipation of a
longer elimination half-life with eribulin-LF compared with
eribulin, which is administered on day 1 and 8 of a 28-day cycle.
The MTD was defined as the highest dose level at which ≤1 of 6
patients experienced a dose-limiting toxicity (DLT).
The dose-expansion phase confirmed safety and tolerability of
the MTD defined in the dose-escalation part of the study and
preliminarily assessed clinical activity of eribulin-LF in patients
with endometrial, ovarian or HER2-negative breast cancer. Study
treatment continued until disease progression, unacceptable
toxicity or withdrawal of patient consent.
A clinical dose of eribulin mesylate 1.4 mg/m2 is equivalent to
1.23 mg/m2 of eribulin expressed as free base. Therefore,
eribulin administered on day 1 and day 8 of a 21-day cycle is
equivalent to 2.46 mg/m2 total dose per cycle. The starting dose
selected for this study was 1.0 mg/m2, which represents a 60%
reduction in the approved eribulin dose administered per cycle
(2.46 mg/m2). Dose increments of 0.5 mg/m2 were planned to
reach 3.5 mg/m2.
Inclusion and exclusion criteria. Patients aged ≥ 18 years with
histologically or cytologically proven advanced solid tumours
refractory to standard therapies were enroled. In the dose-
expansion phase, the following tumours were permitted: endo-
metrial cancer after failure of prior chemotherapy for recurrent,
metastatic or high-risk disease; ovarian cancer after failure of prior
chemotherapy or intolerance of platinum agents (including
patients with platinum-sensitive and platinum-refractory disease);
and breast cancer (HER2-negative subtype) after failure of
previous standard (anthracycline and taxane) chemotherapy
treatments. Patients were required to have had ≥1 measurable
lesion based on Response Evaluation Criteria In Solid Tumours
(RECIST) version (v) 1.1 (dose-expansion phase), an Eastern
Cooperative Oncology Group performance status ≤ 1, and ade-
quate liver, renal and bone marrow function.
Key exclusion criteria included patients having had any antic-
ancer therapy within 21 days prior to study entry for cytotoxic
agents and targeted agents, or within 30 days for an investiga-
tional agent, patients with pre-existing peripheral neuropathy of
National Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE) grade > 1, patients who had previously
been treated with eribulin, and patients who had not recovered
(to grade < 2) from acute toxicities associated with prior anticancer
therapy or had received radiation therapy encompassing > 30% of
the bone marrow.
Dose escalation and reduction. Dose escalation of eribulin-LF
was based on safety and tolerability during the first treatment
cycle. Severe toxicities (defined and graded as CTCAE version
4.03, grade ≥ 3) during later treatment cycles were also
considered. DLTs were defined as any of the following:
neutropenia grade 4 lasting > 5 days; neutropenia grade 3 or 4
complicated by fever and/or infection (absolute neutrophil count
[ANC] < 1.0 × 109/L, fever ≥ 38.5 °C); grade 4 thrombocytopenia of
any duration; grade 3 thrombocytopenia complicated by
bleeding and/or requiring platelet or blood transfusion; grade
3 or 4 hypersensitivity reactions, symptomatic bronchospasm
requiring parenteral medication(s) with or without urticaria or
allergy-related oedema/angioedema and other grade 3/4 clini-
cally significant nonhematologic toxicities (except for inade-
quately treated nausea and/or vomiting) considered related to
the study drug, including peripheral neuropathy. During the
dose-expansion phase, pre-specified dose interruptions and dose
reductions based on prior data from eribulin studies were
permitted if eribulin-LF-related toxicity occurred (see Supple-
mentary Table 1).
Safety analyses. Safety assessments included monitoring and
recording all adverse events (AEs) and serious AEs (SAEs). Patients
underwent monitoring of haematology, blood chemistry, urine
values, vital signs, electrocardiograms (at screening, baseline, day
1 and day 15 of each cycle and within 30 days after the last dose
of study treatment) and physical examinations (at screening,
baseline, day 1 and day 15 of cycle 1, day 1 of each subsequent
treatment cycle and within 30 days after the last dose of study
treatment). Hypersensitivity reactions were considered events of
special interest.
Pharmacokinetic analyses. Blood samples for pharmacokinetic
analyses were collected during cycle 1 and cycle 3 in the dose-
escalation phase and cycle 1 in the dose-expansion phase. For
patients receiving eribulin-LF in Schedule 1, blood samples were
collected on day 1 at predose, 15 min after the start of infusion,
5 min after the end of infusion, 0.5, 1, 2, 4, 6, 8 and 24 h postdose,
and on days 4, 7, 9 and 11. For patients receiving eribulin-LF in
Schedule 2, blood samples were collected on day 1 and day 15 at
predose, 15 min after the start of infusion, 5 min after the end of
infusion, 0.5, 1, 2, 4, 6, 8 and 24 h postdose, and on days 4, 7, 9
and 11.
Urine samples for pharmacokinetic analyses were collected in
the dose-escalation cohort during cycle 1 and cycle 3. For patients
receiving eribulin-LF according to Schedule 1, urine samples were
collected predose, and at 0−24 h (day 1), 24−48 h (day 2), 48−72 h
(day 3) and 72−96 h (day 4). For patients receiving eribulin-LF
according to Schedule 2, urine samples were collected predose,
and at 0−24 h (day 1/day 15), 24−48 h (day 2/day 16), 48−72 h
(day 3/day 17) and 72−96 h (day 4/day 18).
Eribulin plasma concentrations were quantified by liquid
chromatography with tandem mass spectrometry methodology
using a previously validated assay.16 Eribulin concentrations refer
to total eribulin.
Efficacy analyses. Tumours were imaged using computed tomo-
graphy or magnetic resonance imaging, and assessed according
to RECIST v1.117 by study site investigators. In accordance with
RECIST v1.1 recommendations, a confirmatory scan was not
required, as this was a phase 1 study where safety is the primary
endpoint. Imaging was performed at screening (pretreatment)
and after every other cycle (i.e., every 6 weeks after cycle 1, day 1
for Schedule 1 and every 8 weeks after cycle 1, day 1 for Schedule
2). Patients who discontinued study treatment during the dose-
escalation phase without disease progression continued to
undergo tumour assessments every 9 weeks (for Schedule 1) or
every 8 weeks (Schedule 2). Patients in the dose-expansion phase
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who discontinued study treatment without disease progression
had tumour assessments every 8 weeks. Disease-control rate is
defined as the proportion of patients who achieved a best overall
response of complete response or partial response or stable
disease (SD). In order for SD to be deemed the best overall
response, it must occur ≥ 5 weeks (or ≥7 weeks for Schedule 2)
following the first dose of study drug.
STATISTICAL ANALYSIS
Safety and efficacy analyses were based on the safety analysis set,
which included all patients who received ≥1 dose of study drug
and had ≥1 postdose safety assessment. Pharmacokinetic analyses
were based on the pharmacokinetic analysis set, which included
all patients with sufficient pharmacokinetic data to derive ≥1
parameter. The dose-finding analysis set included all patients in
the dose-escalation phase of the study who completed cycle 1
treatment and were evaluable for DLTs, as well as those who
discontinued during cycle 1 due to DLTs. Actual dose intensity is
defined as: total dose received over all treatment cycles (mg/m2)/
(duration of treatments in days/7).
Descriptive summary statistics (mean, standard deviation (SD),
median, minimum and maximum) were determined for all
continuous data (e.g., clinical laboratory test results, vital signs
measurements and changes from baseline), and the number and
percentage of patients were determined for all categorical data
(e.g., baseline patient demographics and clinical characteristics).
The number and percentage of patients reporting treatment
emergent adverse events (TEAEs) were summarised by both
CTCAE grade and relationship to study drug. Efficacy parameters
were summarised separately for patients in the expanded cohorts
for each tumour type. Eribulin pharmacokinetic parameters were
derived from plasma concentrations by noncompartmental
analysis using actual times. Statistical analyses were performed
using SAS, v 9.3 (Cary, NC).
RESULTS
Patient disposition and demographics
The study was conducted between 11 December 2012 and 16 May
2016 at four sites in the United Kingdom. A total of 71 patients
were screened, 58 of whom received treatment (Supplementary
Figure 1): 20 patients in Schedule 1 and 38 patients in Schedule 2.
Baseline demographics are shown in Table 1. Among 20 patients
who received eribulin-LF according to Schedule 1, the majority
were male (11 patients; 55.0%) and the median age was 61.0
years. The most common cancer types were pleural mesothelioma
and uterine cervix cancer (15.0% each). Among the 38 patients
who received eribulin-LF according to Schedule 2, most were
female (29 patients; 76.3%), the median age was 62.5 years, and
the most common cancer types were sites of primary lesion were
ovarian (26.3%), breast (23.7%), and colorectal cancers (23.7%).
Schedule 1 included patients with more diverse tumour types,
whereas Schedule 2 included patients with specific tumour types
(endometrial, ovarian and breast cancers) for the expansion part of
the study. Overall, the majority of patients (>65%) had either
colorectal (n= 11), breast (n= 10), ovarian (n= 10) or endometrial
(n= 7) cancers.
Maximum tolerated dose. DLTs in the dose-escalation phase are
summarised in Table 2. For Schedule 1, the MTD for eribulin-LF
was determined to be 1.4 mg/m2 on day 1 every 21 days. At the
Table 1. Patient demographics and disease characteristics
Parameter Schedule 1
(n= 20)
Schedule 2
(n= 38)
All patients
(n= 58)
Age, years
Median (range) 61.0 (33−75) 62.5 (40−70) 62.0 (33−75)
Sex, n (%)
Male 11 (55.0) 9 (23.7) 20 (34.5)
Female 9 (45.0) 29 (76.3) 38 (65.5)
Race, n (%)
White 19 (95.0) 36 (94.7) 55 (94.8)
Black or African
American
1 (5.0) 1 (2.6) 2 (3.4)
Other 0 1 (2.6) 1 (1.7)
ECOG PS, n (%)
0 4 (20.0) 16 (42.1) 20 (34.5)
1 16 (80.0) 22 (57.9) 38 (65.5)
Prior systemic therapies, n (%)
1 6 (30.0) 4 (10.5) 10 (17.2)
2 9 (45.0) 7 (18.4) 16 (27.6)
3 3 (15.0) 12 (31.6) 15 (25.9)
4 1 (5.0) 4 (10.5) 5 (8.6)
5−14 1 (5.0) 11 (28.9) 12 (20.7)
Tumour type, n (%)
Breast 1 (5.0) 9 (23.7) 10 (17.2)
Cholangiocarcinoma 2 (10.0) 0 2 (3.4)
Colorectala 2 (10.0) 9 (23.7) 11 (19.0)
Endometrial 1 (5.0) 6 (15.8) 7 (12.1)
Gall bladder 2 (10.0) 0 2 (3.4)
NSCLC 1 (5.0) 2 (5.3) 3 (5.2)
Ovarian 0 10 (26.3) 10 (17.2)
Pancreatic 2 (10.0) 1 (2.6) 3 (5.2)
Pleural
mesothelioma
3 (15.0) 0 3 (5.2)
Uterine cervix 3 (15.0) 0 3 (5.2)
Otherb 3 (15.0) 1 (2.6) 4 (6.9)
aIncludes colon, rectum and large intestine (excludes appendix)
bIncludes adrenal glands, duodenal, oesophageal and laryngeal cancers.
ECOG PS Eastern Cooperative Oncology Group performance score, NSCLC
non–small-cell lung cancer
Table 2. Dose-limiting toxicities among patientsa in the dose-
escalation phase
Schedule,
Patient, n
Eribulin-LF
dose
Patient, n DLT
1 (18) 1.5 mg/m2 1 Grade 4
hypophosphatemia
1 Grade 4 increased ALT/AST
2 (12) 1.5 mg/m2 1 Grade 4 febrile
neutropenia
Grade 3 stomatitis
2.0 mg/m2 1 Grade 3 increased ALT
1 Grade 4 neutropenia
aDetermination of the MTD was based on the dose-finding analysis set,
which included all patients in the dose-escalation part who completed
cycle 1 treatment and were evaluated for DLTs, and those who
discontinued cycle 1 during the DLT. Of the 35 patients treated in the
dose-escalation phase, 30 were evaluable for DLTs (n= 18 in Schedule 1
and n= 12 in Schedule 2)
ALT alanine aminotransferase, DLT dose-limiting toxicity, LF liposomal
formulation, MTD maximum tolerated dose
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1.5 mg/m2 dose in Schedule 1, 2 patients had DLTs (grade 4
hypophosphatemia [n= 1], grade 4 increased alanine amino-
transferase/aspartate aminotransferase levels [ALT/AST; n= 1]). An
additional 3 patients were evaluated at a dose of 1.0 mg/m2, none
of whom experienced a DLT. Therefore, an intermediate dose of
1.4 mg/m2 eribulin-LF in Schedule 1 was evaluated in 6 patients,
with none experiencing a DLT. For Schedule 2, the MTD was
determined to be 1.5 mg/m2 on day 1 and day 15 of a 28-day
cycle, with 2 DLTs reported at that dose in 1 patient (grade 4
febrile neutropenia and grade 3 stomatitis). At the 2mg/m2 dose,
3 patients were treated and 2 had DLTs (grade 3 increased ALT
[n= 1] and grade 4 neutropenia [n= 1]).
Exposure. The median (range) number of cycles was 3 (1–26) for
Schedule 1 and 2 (1–12) for Schedule 2. Of the 58 patients who
received treatment, 43 (74.1%) discontinued due to objective
disease progression, 9 (15.5%) due to clinical disease progression,
3 (5.2%) due to patient choice, 1 (1.7%) due to toxicity, 1 (1.7%)
due to AEs, and 1 (1.7%) due to death >30 days after the last dose
of study treatment. The duration of treatment is summarised in
Supplementary Figure 2; the median durations of treatment were
similar for Schedule 1 and Schedule 2 (9 and 8 weeks,
respectively).
Due to dosing frequency, the dose intensity differed between
Schedules 1 and 2 at their respective MTDs. The planned dose
intensity in Schedule 2 was 60% higher than in Schedule 1 (0.75
vs. 0.47 mg/m2/week). At the MTD dose of 1.4 mg/m2 for Schedule
1, the mean actual dose intensity (defined as total dose [mg/m2]
received/[duration of treatment in days/7]) was 0.5 mg/m2/week
per patient, with a mean relative dose intensity (defined as actual
dose intensity/planned dose intensity) of 1.0 (SD= 0.05). For the
Schedule 2 MTD of 1.5 mg/m2 (including both dose-escalation and
dose-expansion patients, n= 32), the actual dose intensity was
0.6 mg/m2/week per patient, with a mean relative dose intensity
of 0.7 (SD= 0.19).
More patients in Schedule 2 had TEAEs leading to dose
interruption than patients in Schedule 1 (60.5% vs. 25.0%). There
was a similar rate of dose reduction due to TEAEs in Schedules 1
and 2 (5.0% vs. 7.9%). Overall, 5 patients (8.6%) experienced TEAEs
that led to study-drug withdrawal (Supplementary Table 2). The
incidence of treatment-related TEAEs leading to study-drug dose
reduction was similar between Schedules 1 and 2 (5.0% vs. 5.3%);
the most common reasons were nonhematological toxicities (ALT
level increase/hypophosphatemia). Treatment-related TEAEs lead-
ing to study-drug dose interruption were more frequent with
Schedule 2 than with Schedule 1 (50% vs. 20%), with neutropenia
being the most frequent cause of drug interruption in Schedule 2
(14 patients; 36.8%).
Safety. Overall, 89.7% of TEAEs were considered treatment
related; this was reported in 18 (90%) patients receiving Schedule
1 and 34 (89.5%) patients receiving Schedule 2 (Supplementary
Table 2). Overall, SAEs were reported in 41.4% of patients and
TEAEs of grade ≥ 3 were reported in 48.2% of patients (60% and
42.1% for Schedules 1 and 2, respectively).
The most frequent TEAEs with Schedule 1 were alopecia
(50.0%), decreased appetite (50.0%), constipation (40.0%), and
diarrhoea (40.0%); and the most frequent TEAEs with Schedule 2
were neutropenia (42.1%), nausea (42.1%), fatigue (34.2%) and
alopecia (34.2%). Overall, the most common grade 3/4 TEAEs were
neutropenia (17.2%), hypophosphatemia (6.9%) and musculoske-
letal chest pain (5.2%) (Table 3). More grade 3/4 events occurred in
Schedule 1 compared with Schedule 2 (60.0% vs. 42.1%,
respectively). However, the overall incidence of grade 3/4
neutropenia was higher in Schedule 2 compared with Schedule
1 (21.1% vs. 10.0%, respectively). A total of 3 (5.2%) patients
experienced grade 3 hypophosphatemia, and 1 (1.7%) patient had
grade 4 hypophosphatemia.
No deaths were reported during the study or within 30 days of
the last dose of study drug. The most frequently reported SAEs
were pyrexia (7 patients; 12.1%) and neutropenia (4 patients;
6.9%). Six patients each treated in Schedule 1 (30%) and in
Schedule 2 (15.8%) had a treatment-related SAE. The most
common treatment-related SAEs were neutropenia (6.9%), febrile
neutropenia/neutropenic sepsis (5 individual patients; 8.6%) and
pyrexia (3.4%) (Supplementary Table 3).
Overall, AEs of special interest were reported in 84.5% of
patients, the most common being asthenia/fatigue (33 patients;
56.9%), alopecia (23 patients; 39.7%), neutropenia (21 patients;
36.2%) and peripheral neuropathy (narrow and broad terms: 11
patients; 19.0%; peripheral sensory neuropathy: 6 patients; 10.3%).
The frequency of treatment-emergent hypersensitivity reactions
was 10.0% (2 patients, both grade 2) in Schedule 1 vs. 7.9% (3
patients: 1 with grade 1 and 2 with grade 2) in Schedule 2. No
grade ≥ 3 hypersensitivity reactions occurred.
Pharmacokinetic analyses. Eribulin plasma-concentration profiles
followed single-phase elimination (Fig. 1a). Exposure to eribulin-LF
was dose dependent and independent of schedule (Figure 1a;
Table 4). Eribulin-LF was eliminated with a mean half-life (t1/2) of
approximately 30 h, with eribulin plasma concentrations quantifi-
able for up to 18 days postdose. Eribulin did not accumulate with
multiple dosing. Eribulin exposure on cycle 3, day 1 was
comparable with that following a single dose on cycle 1, day 1.
Exposure to eribulin-LF was variable and overlapped across doses
and schedules. There was no observed correlation between
eribulin exposure (AUC) and the occurrence of DLTs (Fig. 1b).
For example, grade 4 febrile neutropenia and grade 4 increase in
transaminase levels in patients dosed with 1.5 mg/m2 eribulin-LF
were associated with the lower eribulin exposure observed.
Efficacy. Investigator-assessed tumour responses with eribulin-LF
for schedules 1 and 2 are shown in Supplementary Table 4 and
Supplementary Figure 3. Partial response was observed in 6
(10.3%) patients: 2 (10%) patients treated in Schedule 1 (1 at
1.4 mg/m2 and 1 at 1 mg/m2) and 4 (10.5%) patients treated in
Schedule 2 (3 at 1.5 mg/m2 and 1 at 2.0 mg/m2). Of the 6 partial
responses, 5 were in patients with breast cancer: 1 patient
received Schedule 1 (1 mg/m2) and 4 patients received Schedule 2
(2 mg/m2, n= 1; 1.5 mg/m2, n= 3). For the 6 patients who
achieved partial response, the duration of response ranged from
49 to 297 days (49, 57, 98, 125, 191 and 297 days). Four out of
these six patients had ongoing response at the subsequent
imaging assessment. Of note, these patients had received 1, 2 or 3
prior lines of anticancer therapy (2 patients each). Antitumour
activity was observed at each dose level, and the overall objective
response rate among all 58 patients for the dose-escalation and
dose-expansion phases was 10.3%. Investigator-assessed tumour
responses during the dose-expansion phase are shown in Fig. 2.
The disease-control rate was 80% in patients with breast cancer,
and 40.0% and 42.9% in patients with ovarian and endometrial
cancers, respectively (Supplementary Table 4). The median
duration of treatment was 8 weeks (range: 3–79 weeks) and was
similar between Schedule 1 (9 weeks; range: 3–79 weeks) and
Schedule 2 (8 weeks; range: 4–48 weeks).
DISCUSSION
In this study, the MTD for eribulin-LF was established for each
schedule (Schedule 1: 1.4 mg/m2; Schedule 2: 1.5 mg/m2). Given
that Schedule 2 had both a higher MTD and a higher dose
intensity, which facilitates greater drug exposure and potentially
increased efficacy, it was selected for the dose-expansion phase of
the study.
In this study, 5 patients (8.6%) experienced any-grade hypopho-
sphatemia (4 patients had grade 3 and 1 patient had grade 4). The
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1 patient who experienced a DLT of grade 4 hypophosphatemia at
cycle 1, day 8, had borderline grade 1/2 hypophosphatemia at
study entry. Grade 3/4 hypophosphatemia by laboratory measure-
ments was observed in 3.2% of patients in the phase 3 trial of the
aqueous formulation of eribulin in advanced soft-tissue sarcoma.7
The causative mechanism of this remains unknown. Hypopho-
sphatemia has also been observed in other recent early-phase
clinical trials.18,19 The incidence of peripheral neuropathy (narrow
and broad terms) in this study of eribulin-LF was 19%; this is lower
than that reported in the two phase 3 clinical trials of eribulin in
breast cancer (35% and 27.4%).6,20 The incidence of peripheral
sensory neuropathy in this study (10.3%) was also lower than that
reported in the phase 3 clinical trial of eribulin in soft-tissue
sarcoma (grade 1–2, 19%; grade 3, 2%).9
The actual dose intensity at the MTD was slightly higher for
Schedule 2 than for Schedule 1 (0.6 vs. 0.5 mg/m2/week per
patient); however, the relative dose intensity at the MTD for
Schedule 2 was lower than for Schedule 1 (0.7 vs. 1.0, respectively).
This may be explained by the higher number of dose interruptions
and omissions observed in Schedule 2 patients at the MTD and
dose reductions due to neutropenic events. The difference
between the incidence of neutropenia events in Schedule 1 and
Schedule 2 (20% vs. 42.1%) was investigated, with a particular
focus on 11 patients who experienced a dose interruption due to
neutropenia in Schedule 2 at the eribulin-LF MTD of 1.5 mg/m2. Of
these patients, 8 did not receive the cycle 1, day 15 dose: 7 of
these omissions were due to neutropenia, and 1 was due to
concurrent upper respiratory tract infection and ascites. However,
the criteria for repeat dosing on day 15 included an ANC ≥ 1.5 ×
109/L. All 7 patients did have an ANC < 1.5 × 109/L on cycle 1, day
15 but only 2 of these patients had ANC < 1.0 × 109/L. In addition,
all these patients proceeded with eribulin-LF dosing in cycle 2. The
high number of dose interruptions in Schedule 2 for neutropenia
suggests the protocol criteria for dosing on day 15 of the
treatment cycle (i.e., ANC of ≥1.5 × 109/L) may have been too
stringent. Of the 5 patients with an ANC of < 1.5 × 109/L and ANC
> 1.0 × 109/L, recovery from the neutropenia was rapid and
allowed continued dosing, usually without the need for
granulocyte-colony stimulating factor treatment, demonstrating
that this dose and schedule was, in fact, tolerable. For further
development, therefore, a different dose adjustment criterion for
Schedule 2 could be considered. In addition, our results also
suggest that if a patient cannot tolerate the 28-day schedule of
eribulin-LF, a 21-day schedule may be considered.
A hypersensitivity reaction (grade 2) following constant-rate
infusion occurred in the first patient enroled in the study and
Table 3. TEAEsa of grade 3 or 4 occurring in ≥2% of patients in any treatment group (all cycles)
TEAE, n (%) Schedule 1 (n= 20) Schedule 2 (n= 38) All patients (n= 58)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Any 9 (45.0) 3 (15.0) 9 (23.7) 7 (18.4) 18 (31.0) 10 (17.2)
Blood and lymphatic system disorders
Febrile neutropenia 0 1 (5.0) 1 (2.6) 1 (2.6) 1 (1.7) 2 (3.4)
Neutropenia 2 (10.0) 0 3 (7.9) 5 (13.2) 5 (8.6) 5 (8.6)
Gastrointestinal disorders
Ascites 1 (5.0) 0 0 0 1 (1.7) 0
Nausea 0 (0) 0 (0) 1 (2.6) 0 1 (1.7) 0
Stomatitis 0 (0) 0 (0) 2 (5.3) 0 2 (3.4) 0
General disorders and administration-site conditions
Device occlusion 1 (5.0) 0 0 0 1 (1.7) 0
Pyrexia 2 (10) 0 (0) 0 0 2 (3.4) 0
Infections and infestations
Neutropenic sepsis 1 (5.0) 0 1 (2.6) 0 2 (3.4) 0
Sepsis 0 0 0 1 (2.6) 0 1 (1.7)
Upper respiratory tract infection 0 0 2 (5.3) 0 2 (3.4) 0
Urinary tract infection 0 0 2 (5.3) 0 2 (3.4) 0
Wound infection 0 0 1 (2.6) 0 1 (1.7) 0
Metabolism and nutrition disorders
Hypernatremia 0 0 1 (2.6) 0 1 (1.7) 0
Hypomagnesemia 0 0 1 (2.6) 0 1 (1.7) 0
Hypophosphatemia 0 1 (5.0) 3 (7.9) 0 3 (5.2) 1 (1.7)
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain 2 (10.0) 0 (0) 1 (2.6) 0 3 (5.2) 0
Investigations
Alanine aminotransferase level increased 0 0 1 (2.6) 0 1 (1.7) 0
Respiratory, thoracic, and mediastinal disorders
Pleuritic pain 1 (5.0) 0 0 0 1 (1.7) 0
Pulmonary embolism 1 (5.0) 0 0 0 1 (1.7) 0
aIf a patient had two or more adverse events with the same preferred term with different CTCAE grades, the event with the highest grade was used.
CTCAE Common Terminology Criteria for Adverse Events, TEAE treatment-emergent adverse event
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Table 4. Eribulin plasma pharmacokinetic parameters (dose-escalation phase; cycle 1, day 1)
Parameter, mean
(standard
deviation)
Schedule 1 Schedule 2
Eribulin-LF dose Eribulin-LF dose
1.0 mg/m2 (n= 6) 1.4 mg/m2 (n= 6) 1.5 mg/m2 (n= 7) 1.0mg/m2 (n= 3) 1.5 mg/m2 (n= 9) 2.0 mg/m2 (n= 3)
AUC0-inf, ng h/mL 27,283.3 (5087.80) 30,366.7 (6062.23) 33,614.3 (13874.13) 12,820.0 (7870.43) 32,364.4 (11900.94) 49,400.0 (8179.85)
Cmax, ng/mL 1986.2 (3084.77) 1119.8 (205.71) 1211.3 (293.35) 665.3 (125.13) 1213.3 (259.42) 1473.3 (47.26)
tmax, h
a 1.95 (0.92, 4.77) 2.835 (1.50, 5.00) 2.00 (0.98, 5.08) 0.82 (0.23, 0.95) 1.13 (0.95, 2.92) 2.10 (1.18, 2.17)
t1/2, h 22.20 (2.212) 23.62 (4.614) 34.87 (19.374) 36.83 (32.679) 28.07 (9.386) 21.13 (3.837)
CL, mL/h 60.15 (17.500) 75.93 (22.818) 80.90 (29.390) 148.63 (61.905) 95.82 (58.289) 65.37 (8.465)
Vd, mL 1953.3 (547.53) 2091.7 (505.03) 2310.0 (514.39) 3793.3 (1866.61) 2873.3 (1530.20) 1993.3 (96.09)
aMedian (min, max)
AUC0-inf area under the concentration–time curve from zero time extrapolated to infinite time, AUC0-t area under the concentration–time curve from zero time
to time of last quantifiable concentration, Cmax maximum observed concentration, CL total clearance, LF liposomal formulation, tmax time at which the highest
drug concentration occurs, t1/2 terminal elimination phase half-life, Vd volume of distribution
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Fig. 1 Pharmacokinetic profile of eribulin-LF. Mean plasma concentration–time curves of eribulin by dose of eribulin-LF on a linear scale and
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occurred again in the second cycle in the same patient. This event
was considered a complement-activation-related pseudo allergy
associated with the liposomal lipid component of the formula-
tion.21 As a result, the protocol for this study was amended to
introduce a stepped-escalation infusion rate for eribulin-LF,
starting at an infusion rate of 0.005mg/min for the first 10 min,
which could be escalated (if tolerated without reaction) to a rate
not exceeding 0.2 mg/min. Following this change in protocol, 7%
of patients experienced grade 1/2 hypersensitivity reactions on a
single occasion, and no grade ≥ 3 hypersensitivity reactions
occurred. No prophylaxis premedication was administered to
manage these events.
Eribulin-LF has a single-phase pharmacokinetic profile, which
differs from the pharmacokinetic profile of the aqueous formula-
tion of eribulin, which has been described as either biphasic22 or
triphasic.23 The elimination t1/2 (~30 h, range: 21.1–36.8) of
eribulin-LF is comparable to that of eribulin (~40−48 h), but the
maximum observed concentration (Cmax) is approximately 5-fold
greater and the AUC is approximately 40-fold greater with
eribulin-LF.22,23 The liposomal formulation enabled longer expo-
sure to eribulin, with the plasma concentration quantifiable up to
18 days postdose, compared with 8 days postdose for eribulin
aqueous formulation.24 Eribulin-LF clearance (CL) and volume of
distribution were much lower than those for eribulin (CL= ~3.4 L/
h for eribulin and 0.08 L/h for eribulin-LF; volume of distribution of
approximately 134 L for eribulin and ~2 L for eribulin-LF).14,15
These observations are in line with doxorubicin liposomal
formulation and are the disposition characteristics of a liposomal
formulation.25 The longer duration of exposure of eribulin-LF
(18 days vs. 8 days) is also due to a ~40-fold greater AUC following
the same magnitude of eribulin dose.
Several liposomal formulations of anticancer drugs have been
approved in various tumour types, including a PEGylated
liposomal formulation of doxorubicin.26 The liposomal formulation
of doxorubicin demonstrated a lower volume of distribution (4.1
vs. 254 L) and clearance (0.1 vs. 45.3 L/h), and a drug concentration
in the tumour that was 4–16 times higher than free doxorubicin.25
Moreover, cardiotoxicity was reduced with the PEGylated liposo-
mal formulation.26,27 Given the potential for reduced toxicity with
liposomal formulations, eribulin-LF may facilitate combinations
with other anticancer agents.
Overall, no new or unexpected safety signals were identified
with eribulin-LF compared to the eribulin aqueous formulation.
The objective response rate in patients with breast cancer in this
study compared favourably with data from pooled analyses from 2
phase 3 studies of eribulin.10 Although these results are encoura-
ging, the sample size of the breast cancer group was small and,
therefore, robust conclusions could not be drawn. Further
investigation of eribulin-LF in breast cancer as a single-agent and
in combination with other therapeutics is under consideration.
CONCLUSIONS
This first-in-human study met its primary objective of establishing
the MTD of eribulin-LF at 1.4 mg/m2 for Schedule 1 (day 1 every
21 days) and 1.5 mg/m2 for Schedule 2 (day 1 and day 15 every
28 days). In this study, eribulin-LF was well tolerated with an AE
profile similar to that of aqueous eribulin. Safety results were
similar across the tumour types evaluated. The pharmacokinetic
profile of eribulin-LF showed the anticipated characteristics of a
liposomal formulation. Eribulin-LF showed preliminary activity in
several tumour types, including breast, endometrial and ovarian
cancers.
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